

SERES THERAPEUTICS, INC.

SCIENCE AND CLINICAL DEVELOPMENT COMMITTEE CHARTER

A. PURPOSE

The purpose of the Science and Clinical Development Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Seres Therapeutics, Inc. (the “*Company*”) is to assist the Board in its oversight of research and development and clinical development activities by the Company, and to provide advice to the Board and the Company’s management regarding such activities.

B. STRUCTURE AND MEMBERSHIP

1. Number. The Committee shall consist of such number of directors as the Board shall from time to time determine.
2. Chair. Unless the Board elects a Chair of the Committee, the Committee shall elect a Chair by majority vote.
3. Compensation. The compensation of Committee members shall be as determined by the Board.
4. Selection and Removal. Members of the Committee shall be appointed by the Board. The Board may remove members of the Committee from the Committee, with or without cause.

C. AUTHORITY AND RESPONSIBILITIES

1. General. The Committee shall discharge its responsibilities and shall assess the information provided to it by the Company’s management and others, in accordance with its business judgment. In addition to the duties and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities consistent with this Charter, the purposes of the Committee, and the Company’s amended and restated bylaws.
2. Research & Development Matters. The Committee shall periodically review the Company’s current and planned research and development strategy, programs and initiatives and shall advise the Board and the Company’s management regarding these matters.
3. Clinical Development Matters. The Committee shall oversee the Company’s current and planned clinical development strategy and programs and shall advise the Board and the Company’s management regarding these matters.
4. Regulatory. The Committee shall provide strategic advice to the Company’s management and the Board regarding clinical development-related regulatory discussions with applicable agencies.

5. Additional Duties. The Committee shall have such other duties as may be delegated from time to time by the Board.

D. PROCEDURES AND ADMINISTRATION

1. Meetings. The Committee shall meet as often as it deems necessary in order to perform its responsibilities. The Committee may also act by unanimous written consent in lieu of a meeting. The Committee shall keep such records of its meetings as it shall deem appropriate.

2. Subcommittees. The Committee may form and delegate authority to one or more subcommittees as it deems appropriate from time to time under the circumstances (including a subcommittee consisting of a single member).

3. Reports to the Board. The Committee shall report regularly to the Board.

4. Charter. The Committee shall periodically review and reassess the adequacy of this Charter and recommend any proposed changes to the Board for approval.

5. Independent Advisors. The Committee is authorized, without further action by the Board, to engage such independent legal and other advisors as it deems necessary or appropriate to carry out its responsibilities. Such independent advisors may be the regular advisors to the Company. The Committee is empowered, without further action by the Board, to cause the Company to pay the compensation of such advisors as established by the Committee.

6. Self-Evaluation. The Committee shall periodically evaluate its own performance and report to the Board on that self-evaluation.

* * * * *